Literature DB >> 14566860

NF2: the wizardry of merlin.

Guang-Hui Xiao1, Jonathan Chernoff, Joseph R Testa.   

Abstract

Neurofibromatosis type II (NF2) is an autosomal dominant cancer syndrome characterized by the formation of tumors of the nervous system, particularly schwannomas and meningiomas. The NF2 gene is also implicated in the development of sporadic schwannomas and meningiomas, as well as tumor types seemingly unrelated to the NF2 disorder, such as malignant mesotheliomas. Inactivation of NF2 occurs by a "two-hit" mechanism, as proposed by Al Knudson, and the NF2 gene behaves as a classical tumor suppressor gene. The NF2 gene product, merlin, exhibits homology with the ezrin-radixin-moesin family of membrane-cytoskeleton-linking proteins. During the past several years, there has been intensive investigation aimed at elucidating the mechanisms underlying merlin's functions. In this review, we summarize the involvement of NF2 inactivation in tumorigenesis. We also discuss observations implicating merlin in cell motility and cell proliferation, with a focus on recent findings linking merlin to Rac signaling. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566860     DOI: 10.1002/gcc.10282

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling.

Authors:  Brett J Pellock; Eugene Buff; Kristin White; Iswar K Hariharan
Journal:  Dev Biol       Date:  2006-12-15       Impact factor: 3.582

2.  Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Authors:  Hansoo Lee; Donghwa Kim; Han C Dan; Eric L Wu; Tatiana M Gritsko; Chuanhai Cao; Santo V Nicosia; Erica A Golemis; Wanguo Liu; Domenico Coppola; Steven S Brem; Joseph R Testa; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

3.  Activation of p21-activated kinase 2 by human immunodeficiency virus type 1 Nef induces merlin phosphorylation.

Authors:  Bangdong L Wei; Vivek K Arora; Alexa Raney; Lillian S Kuo; Guang-Hui Xiao; Eduardo O'Neill; Joseph R Testa; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 4.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

5.  Molecular genetics alterations and tumor behavior of sporadic vestibular schwannoma from the People's Republic of China.

Authors:  Liu-Guan Bian; Wuttipong Tirakotai; Qing-Fang Sun; Wei-Guo Zhao; Jian-Kang Shen; Qi-Zhong Luo
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

6.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

Review 7.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

8.  MicroRNA-146b-3p Promotes Cell Metastasis by Directly Targeting NF2 in Human Papillary Thyroid Cancer.

Authors:  Chunxiao Yu; Li Zhang; Dandan Luo; Fang Yan; Jia Liu; Shanshan Shao; Lifang Zhao; Tong Jin; Jiajun Zhao; Ling Gao
Journal:  Thyroid       Date:  2018-10-27       Impact factor: 6.568

Review 9.  The biological underpinnings of radiation therapy for vestibular schwannomas: Review of the literature.

Authors:  Mark C Dougherty; Seiji B Shibata; Marlan R Hansen
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-30

Review 10.  Neurofibromatosis.

Authors:  P A Gerber; A S Antal; N J Neumann; B Homey; C Matuschek; M Peiper; Wilfried Budach; E Bölke
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.